Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges.
作者： Madhav V. Dhodapkar , Joshua Richter
DOI: 10.1016/J.CLIM.2010.12.010
关键词:
摘要: Multiple myeloma is a hematologic malignancy characterized by growth of malignant plasma cells in the bone marrow. Tumor express CD1d and are sensitive to lysis restricted natural killer T (NKT) cells. Here we discuss recent studies harness properties these context human myeloma. In spite large body preclinical data, attempts fully clinic early stages. Early phase clinical document capacity monocyte-derived dendritic expand NKT vivo patients. These results have set stage for ongoing combining activation with immune-modulatory drugs. Lessons learnt from may inform optimal application based therapies other settings as well.
elsevier.com
sci-hub.se 参考文章(60)
Dale I. Godfrey, H. Robson MacDonald, Mitchell Kronenberg, Mark J. Smyth, Luc Van Kaer, NKT cells: what's in a name? Nature Reviews Immunology. ,vol. 4, pp. 231- 237 ,(2004) , 10.1038/NRI1309
Masaki Terabe, So Matsui, Nancy Noben-Trauth, Hangjiong Chen, Cynthia Watson, Debra D. Donaldson, David P. Carbone, William E. Paul, Jay A. Berzofsky, NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nature Immunology. ,vol. 1, pp. 515- 520 ,(2000) , 10.1038/82771
Luc Van Kaer, Hideo Yagita, Ikuo Saiki, Ko Okumura, Mark J. Smyth, Yoshihiro Hayakawa, Kazuyoshi Takeda, IFN-γ–mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, α-galactosylceramide Blood. ,vol. 100, pp. 1728- 1733 ,(2002) , 10.1182/BLOOD.V100.5.1728.H81702001728_1728_1733
Madhav, V. Dhodapkar, Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges Frontiers in Bioscience. ,vol. Volume, pp. 796- 807 ,(2009) , 10.2741/3278
Randy R. Brutkiewicz, CD1d Ligands: The Good, the Bad, and the Ugly Journal of Immunology. ,vol. 177, pp. 769- 775 ,(2006) , 10.4049/JIMMUNOL.177.2.769
Mark A. Exley, Syed Muhammad Ali Tahir, Olivia Cheng, Angela Shaulov, Robin Joyce, David Avigan, Robert Sackstein, Steven P. Balk, A major fraction of human bone marrow lymphocytes are Th2-like CD1d-reactive T cells that can suppress mixed lymphocyte responses. Journal of Immunology. ,vol. 167, pp. 5531- 5534 ,(2001) , 10.4049/JIMMUNOL.167.10.5531
Vrajesh V. Parekh, Saif Lalani, Sungjune Kim, Ramesh Halder, Miyuki Azuma, Hideo Yagita, Vipin Kumar, Lan Wu, Luc Van Kaer, PD-1/PD-L Blockade Prevents Anergy Induction and Enhances the Anti-Tumor Activities of Glycolipid-Activated Invariant NKT Cells Journal of Immunology. ,vol. 182, pp. 2816- 2826 ,(2009) , 10.4049/JIMMUNOL.0803648
Weiming Yuan, Suk-Jo Kang, James E. Evans, Peter Cresswell, Natural lipid ligands associated with human CD1d targeted to different subcellular compartments. Journal of Immunology. ,vol. 182, pp. 4784- 4791 ,(2009) , 10.4049/JIMMUNOL.0803981
Syed Muhammad Ali Tahir, Olivia Cheng, Angela Shaulov, Yasuhiko Koezuka, Glenn J. Bubley, S. Brian Wilson, Steven P. Balk, Mark A. Exley, Loss of IFN-γ Production by Invariant NK T Cells in Advanced Cancer The Journal of Immunology. ,vol. 167, pp. 4046- 4050 ,(2001) , 10.4049/JIMMUNOL.167.7.4046
Tetsu Kawano, Toshinori Nakayama, Noriaki Kamada, Yoshikatsu Kaneko, Michishige Harada, Nobutaka Ogura, Yasunori Akutsu, Shinichiro Motohashi, Toshihiko Iizasa, Hideharu Endo, Takehiko Fujisawa, Hiroshi Shinkai, Masaru Taniguchi, Antitumor Cytotoxicity Mediated by Ligand-activated Human Vα24 NKT Cells Cancer Research. ,vol. 59, pp. 5102- 5105 ,(1999)